Skip to main content
欧康医药 logo

欧康医药 — Investor Relations & Filings

Ticker · 920230 Beijing Stock Exchange Manufacturing
Open in API
Filings indexed 373 across all filing types
Latest filing 2023-08-23 Interim / Quarterly Rep…
Country CN China
Listing Beijing Stock Exchange 920230

About 欧康医药

https://www.okaypharm.com/

Oukang Pharmaceutical specializes in the research, development, and large-scale production of natural plant extracts, with a primary focus on citrus-derived flavonoids. The company’s core product portfolio includes high-purity ingredients such as Hesperidin, Diosmin, Methyl Hesperidin, and Neohesperidin Dihydrochalcone (NHDC). These products serve as essential raw materials for the global pharmaceutical, nutraceutical, food and beverage, and cosmetic sectors. Utilizing advanced extraction and purification technologies, the company maintains rigorous quality control standards to ensure compliance with international regulatory requirements. Its operations emphasize the industrialization of plant-based chemical derivatives to support diverse health and wellness applications.

Recent filings

Filing Released Lang Actions
2023年半年度报告
Interim / Quarterly Report Classification · 100% confidence The document is titled as a "半年度报告" which translates to "Half-Year Report" or "Interim Report" for the period January 1, 2023 to June 30, 2023. It contains detailed financial data including income, profit, assets, liabilities, and operational performance metrics. The document is about 15,000 characters long, indicating it is a full report rather than a brief announcement. It includes sections such as company overview, financial data, business review, and risk analysis, which are typical of an interim or quarterly report. There is no indication that this is an annual report (10-K), audit report, or earnings release. The presence of comprehensive financial statements and analysis for a half-year period aligns with the definition of an Interim / Quarterly Report (IR). H1 2023
2023-08-23 Chinese
独立董事关于第三届董事会第二十次会议相关事项的独立意见
Regulatory Filings Classification · 95% confidence The document is an independent directors' opinion on the company's 2023 semi-annual report and a special report on the use of raised funds for the same period. It references the 2023 half-year report and related agenda items but does not contain the actual financial statements or detailed financial data itself. The document is relatively short (908 characters) and serves as an opinion or certification regarding the reports rather than the reports themselves. Therefore, it is not the interim/quarterly report (IR) but rather a regulatory filing related to governance and compliance. Given the nature and length, it fits best under Regulatory Filings (RNS).
2023-08-23 Chinese
关于设立分公司的公告
Board/Management Information Classification · 95% confidence The document is an announcement regarding the establishment of a branch office by Chengdu Oukang Pharmaceutical Co., Ltd. It details the board meeting resolution approving the establishment of the branch, its purpose, and its impact on the company. There is no financial data, no mention of annual or quarterly reports, no voting results, no executive changes, and no regulatory filings of financial nature. The document is a corporate announcement about management decisions related to company structure, specifically the setting up of a branch office. This fits best under Board/Management Information (MANG) as it involves a board resolution and management decision about company operations.
2023-08-23 Chinese
第三届董事会第二十次会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of the resolutions passed at the 20th meeting of the 3rd Board of Directors of Chengdu Oukang Pharmaceutical Co., Ltd. It details the meeting logistics, attendance, and voting results on several agenda items, including approval of the 2023 semi-annual report and related disclosures, a special report on the use of raised funds, and the establishment of a branch company. The document references other filings where the actual reports are published, indicating this document itself is a board meeting resolution announcement rather than the reports themselves. This fits the category of Board/Management Information (MANG), which covers announcements of board decisions and management changes. The document length is short (1777 characters) and does not contain financial statements or detailed financial data, so it is not an Interim/Quarterly Report or Annual Report. Therefore, the correct classification is MANG with high confidence.
2023-08-23 Chinese
2023年半年度募集资金存放与实际使用情况的专项报告
Capital/Financing Update Classification · 95% confidence The document is titled as a "专项报告" (special report) on the status of raised funds (募集资金) usage and storage by Chengdu Oukang Pharmaceutical Co., Ltd. It details the amount of funds raised, their allocation, usage during the reporting period, and compliance with regulatory requirements. It references approvals from the China Securities Regulatory Commission and includes detailed financial figures on fundraising and usage. The document is about the management and actual use of capital raised through a public stock issuance, which fits the category of Capital/Financing Update (CAP). The document length is 3690 characters, which is relatively short but contains substantive financial data on fundraising and usage, not just an announcement or certification. Therefore, it is not a Report Publication Announcement or Regulatory Filing. It is not an Annual Report, Interim Report, or Earnings Release, as it focuses specifically on fundraising and capital usage. Hence, the best classification is Capital/Financing Update (CAP).
2023-08-23 Chinese
2023年半年度报告摘要
Interim / Quarterly Report Classification · 95% confidence The document is titled as a "半年度报告摘要" which translates to "Half-Year Report Summary" for the year 2023. It contains detailed financial data such as total assets, net profit, earnings per share, and other financial metrics for the half-year period. It also includes company business descriptions, shareholder information, and notes on asset pledges and restrictions. The document explicitly states it is an unaudited half-year report summary and references the full half-year report. The length of the document (5905 characters) and the presence of substantive financial data and analysis confirm it is a financial report for a period shorter than a full fiscal year. Therefore, this document fits the definition of an Interim / Quarterly Report (IR). H1 2023
2023-08-23 Chinese

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.